AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22471452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=474 smokers, mean age=44.56 years, SD=9.66 years)
Number of subjects: 3304
Study 22471452 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=454 smokers, mean age=44.47 years, SD=10.30 years)
Number of subjects: 3304
Study 19908338 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Enteroclysis (MRE)
Number of subjects: 108
Study 19908338 — intervention group
Group type: COMPARATOR
Intervention: MR Follow-Through (MRFT)
Number of subjects: 108
Study 16814292 — intervention group
Group type: COMPARATOR
Intervention: Regularly menstruating exercising control women
Number of subjects: 3
Study 16814292 — intervention group
Group type: COMPARATOR
Intervention: Regularly menstruating normally active control women
Number of subjects: 3
Study 16814292 — intervention group
Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 3
Study 12732859 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (CS)
Number of subjects: 0
Study 12732859 — intervention group
Group type: COMPARATOR
Intervention: Open suction (OS)
Number of subjects: 0
Study 10902994 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg iron + either 1171 or 209 kJ
Number of subjects: 36
Study 10902994 — intervention group
Group type: COMPARATOR
Intervention: 104 kJ + 0 iron
Number of subjects: 36
Study 8881899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 5 mg/kg per day decreasing to 3 mg/kg per day (Group A)
Number of subjects: 78
Study 8881899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 3 mg/kg per day increasing to 5 mg/kg per day (Group B)
Number of subjects: 78
Study 1328784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 I.U. heparin administered twice daily
Number of subjects: 594
Study 1328784 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (3000 I.U. anti-Xa) administered daily
Number of subjects: 594
Study 1328784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (heparin and low molecular weight heparin)
Number of subjects: 594
Study 1328784 — intervention group
Group type: COMPARATOR
Intervention: Excluded group (patients with contraindications)
Number of subjects: 594
Study 3904393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15
Study 3904393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3305116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes
Number of subjects: 15
Study 3305116 — intervention group
Group type: COMPARATOR
Intervention: Control (no pancreatic enzymes)
Number of subjects: 15
Study 30454051 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component community-based rehabilitation programme
Number of subjects: 0
Study 30454051 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 28916603 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide (0.05 mg/kg per hour intravenous infusion)
Number of subjects: 14
Study 28916603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26333337 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of monovalent influenza A H1N1 vaccine
Number of subjects: 24
Study 26333337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23940221 — intervention group
Group type: EXPERIMENTAL
Intervention: iAMP21 (intrachromosomal amplification of chromosome 21)
Number of subjects: 7793
Study 23940221 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 29 MRD ≥ 0.01% and iAMP21
Number of subjects: 7793
Study 23940221 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of both iAMP21 and MRD
Number of subjects: 7793
Study 23940221 — intervention group
Group type: COMPARATOR
Intervention: iAMP21
Number of subjects: 7793
Study 20490632 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-step facilitated (TSF) group treatment
Number of subjects: 49
Study 20490632 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping-enhanced cognitive-behavioral group therapy (CBGT-mapping)
Number of subjects: 49
Study 20490632 — intervention group
Group type: COMPARATOR
Intervention: Wait-List control
Number of subjects: 49
Study 18805240 — intervention group
Group type: EXPERIMENTAL
Intervention: MUS patients
Number of subjects: 43
Study 18805240 — intervention group
Group type: COMPARATOR
Intervention: Mild simulators
Number of subjects: 43
Study 18805240 — intervention group
Group type: COMPARATOR
Intervention: Strong simulators
Number of subjects: 43
Study 16579490 — intervention group
Group type: EXPERIMENTAL
Intervention: fast‐acting WDRC
Number of subjects: 50
Study 16579490 — intervention group
Group type: EXPERIMENTAL
Intervention: slow‐acting AVC
Number of subjects: 50
Study 16579490 — intervention group
Group type: COMPARATOR
Intervention: nonlinear fittings
Number of subjects: 50
Study 16579490 — intervention group
Group type: COMPARATOR
Intervention: linear reference fittings
Number of subjects: 50
Study 14552398 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions with various analogous tasks; specific details on dosage and duration not available.
Number of subjects: 0
Study 14552398 — intervention group
Group type: COMPARATOR
Intervention: Positive-capture strategy; specific details on dosage and duration not available.
Number of subjects: 0
Study 10944130 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha2a plus 13‐CRA
Number of subjects: 284
Study 10944130 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha2a alone
Number of subjects: 284
Study 10944130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 284
Study 10944130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFNalpha2a plus 13‐CRA)
Number of subjects: 284
Study 8823826 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting electrodes
Number of subjects: 20
Study 8823826 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid electrodes
Number of subjects: 20
Study 1485705 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoderm topical application
Number of subjects: 50
Study 1485705 — intervention group
Group type: COMPARATOR
Intervention: Usual conservative treatment
Number of subjects: 50
Study 3922732 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (7.5 mg/kg intravenously over 5 minutes followed by oral administration for 3 weeks)
Number of subjects: 19
Study 3922732 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (0.8 mg sublingually)
Number of subjects: 19
Study 3922732 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (0.15 mg/kg intravenously)
Number of subjects: 19
Study 3922732 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (5 ng/kg/min)
Number of subjects: 19
Study 31384906 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG water laser treatment
Number of subjects: 272
Study 31384906 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide paste (control group)
Number of subjects: 272
Study 29379043 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall-antigen stimulation
Number of subjects: 76
Study 29379043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitogen stimulation
Number of subjects: 76
Study 29379043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 76
Study 29379043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low arterial oxygen tension (PaO2)
Number of subjects: 76
Study 27113429 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL‐PDT
Number of subjects: 601
Study 27113429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 601
Study 27113429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 601
Study 25262525 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises group
Number of subjects: 68
Study 25262525 — intervention group
Group type: COMPARATOR
Intervention: General exercises group
Number of subjects: 68
Study 22445107 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-antiviral combination therapy
Number of subjects: 45
Study 22445107 — intervention group
Group type: COMPARATOR
Intervention: Steroid-only treatment
Number of subjects: 45
Study 22445107 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSH with pain
Number of subjects: 45
Study 20436102 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching
Number of subjects: 8
Study 20436102 — intervention group
Group type: EXPERIMENTAL
Intervention: More abrasive dentifrice
Number of subjects: 8
Study 20436102 — intervention group
Group type: EXPERIMENTAL
Intervention: Less abrasive dentifrice
Number of subjects: 8
Study 20436102 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion
Number of subjects: 8
Study 18676418 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted instruction
Number of subjects: 37
Study 18676418 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 37
Study 16424846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia followed by 2‐minute blood warm reperfusion
Number of subjects: 70
Study 16424846 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia with no reperfusion
Number of subjects: 70
Study 16424846 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropic support
Number of subjects: 70
Study 16424846 — intervention group
Group type: EXPERIMENTAL
Intervention: No inotropic support
Number of subjects: 70
Study 12162473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 200 mg
Number of subjects: 500
Study 12162473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 400 mg
Number of subjects: 500
Study 12162473 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen 200 mg
Number of subjects: 500
Study 12162473 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen 400 mg
Number of subjects: 500
Study 12162473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate
Number of subjects: 500
Study 12162473 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen
Number of subjects: 500
Study 10682464 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna treatment (1 tablet daily) in preventive group (n = 96)
Number of subjects: 369
Study 10682464 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna treatment (1 tablet daily) in treatment group (n = 93)
Number of subjects: 369
Study 10682464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation) in preventive group (n = 95)
Number of subjects: 369
Study 10682464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (0.3 g tid/d) in treatment group (n = 50)
Number of subjects: 369
Study 10682464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroids (1 tablet/d) in treatment group (n = 35)
Number of subjects: 369
Study 7648860 — intervention group
Group type: COMPARATOR
Intervention: 0% CO2
Number of subjects: 0
Study 7648860 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% CO2
Number of subjects: 0
Study 7648860 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 0
Study 7648860 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% CO2
Number of subjects: 0
Study 2930094 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit for Life program training (3 hours)
Number of subjects: 81
Study 2930094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 81
Study 2930094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of trained internists
Number of subjects: 81
Study 2930094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of trained internists who wanted to quit
Number of subjects: 81
Study 683275 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (2 mg per day)
Number of subjects: 4
Study 683275 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 4
Study 683275 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of glucagon
Number of subjects: 4
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: weighted genetic risk score (wGRS) based on four APOE-independent SNPs
Number of subjects: 1259
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: combined model with wGRS and APOE E4 genotypes
Number of subjects: 1259
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: cGRS based on seven SNPs
Number of subjects: 1259
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: wGRS based on seven SNPs
Number of subjects: 1259
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: cGRS based on four APOE-independent SNPs
Number of subjects: 1259
Study 31346968 — intervention group
Group type: EXPERIMENTAL
Intervention: wGRS based on four APOE-independent SNPs
Number of subjects: 1259
Study 29425226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlets and one poster on influenza vaccine in GPs' waiting rooms (intervention group)
Number of subjects: 10597
Study 29425226 — intervention group
Group type: COMPARATOR
Intervention: Standard waiting rooms without additional advertising (control group)
Number of subjects: 10597
Study 26258655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg kg⁻¹ i.v. 30 minutes before surgery
Number of subjects: 105
Study 26258655 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 105
Study 25011949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1 mg otelixizumab administered over 8 days
Number of subjects: 281
Study 25011949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 25011949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1 mg otelixizumab
Number of subjects: 281
Study 21722284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 156
Study 21722284 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 156
Study 20926152 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 38570
Study 20926152 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD without asthmatic symptoms
Number of subjects: 38570
Study 17989535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0
Study 17989535 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 0
Study 17989535 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled designs
Number of subjects: 0
Study 15891593 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection gated SPECT with 99mTc tetrofosmin performed 3 days after primary PCI
Number of subjects: 45
Study 15891593 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection gated SPECT with 99mTc tetrofosmin
Number of subjects: 45
Study 12486510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 0.005% latanoprost and 0.5% timolol once daily in the morning
Number of subjects: 436
Study 12486510 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost once daily in the morning
Number of subjects: 436
Study 12486510 — intervention group
Group type: COMPARATOR
Intervention: Timolol twice daily
Number of subjects: 436
Study 9293599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hiking sticks
Number of subjects: 15
Study 9293599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hiking stick
Number of subjects: 15
Study 9293599 — intervention group
Group type: COMPARATOR
Intervention: 0 hiking sticks
Number of subjects: 15
Study 9293599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hiking sticks with load
Number of subjects: 15
Study 9293599 — intervention group
Group type: COMPARATOR
Intervention: 0 hiking sticks with load
Number of subjects: 15
Study 8048625 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter deconvolution analysis
Number of subjects: 0
Study 2979244 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (2 g b.d.)
Number of subjects: 20
Study 2979244 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 20
Study 29889762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 80
Study 29889762 — intervention group
Group type: COMPARATOR
Intervention: Bilateral tubal ligation
Number of subjects: 80
Study 28094136 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 31
Study 28094136 — intervention group
Group type: COMPARATOR
Intervention: Usual pump therapy
Number of subjects: 31
Study 26351349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 or 3 mg/kg, intravenous infusion every 2 weeks)
Number of subjects: 20
Study 24271253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-exit alarm system
Number of subjects: 98
Study 24271253 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 98
Study 20951491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration
Number of subjects: 310
Study 20951491 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 310
Study 18465331 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy with postoperative radiotherapy
Number of subjects: 425
Study 18465331 — intervention group
Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 425
Study 18465331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stage I tumours
Number of subjects: 425
Study 18465331 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I tumours
Number of subjects: 425
Study 18465331 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal patients
Number of subjects: 425
Study 18465331 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal patients
Number of subjects: 425
Study 18465331 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 425
Study 16472041 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB-based HIV risk-avoidance intervention
Number of subjects: 557
Study 16472041 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 557
Study 14527113 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist extension orthosis
Number of subjects: 0
Study 14527113 — intervention group
Group type: COMPARATOR
Intervention: Free hand
Number of subjects: 0
Study 11185669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (12 g/d) in addition to chronic statin therapy
Number of subjects: 25
Study 11185669 — intervention group
Group type: COMPARATOR
Intervention: Control group (statin therapy only)
Number of subjects: 25
Study 9365450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine 1.9 mg/kg every 12 h plus intravenous placebo (saline)
Number of subjects: 56
Study 9365450 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.04 mg/kg/h plus placebo tablet
Number of subjects: 56
Study 7917912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 fragments intravenously at doses of 1, 3 and 5 micrograms kg‐1 body weight during s.c. IL‐2 treatment.
Number of subjects: 12
Study 7917912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at MTD of 5 micrograms kg‐1.
Number of subjects: 12
Study 7917912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms kg‐1.
Number of subjects: 12
Study 7917912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at 5 micrograms kg‐1.
Number of subjects: 12
Study 7917912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 treatment.
Number of subjects: 12
Study 2844088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 130
Study 2844088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 29510762 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Body Image programme (intervention group)
Number of subjects: 2481
Study 29510762 — intervention group
Group type: COMPARATOR
Intervention: Control condition (control group)
Number of subjects: 2481
Study 28252882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) combined with Treatment as Usual (TAU)
Number of subjects: 80
Study 28252882 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 80
Study 25494333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (6-month duration)
Number of subjects: 60
Study 25494333 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi experts (no intervention)
Number of subjects: 60
Study 23217149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedists - Range of Motion (ROM)
Number of subjects: 109
Study 23217149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedists - Muscle Strength
Number of subjects: 109
Study 23217149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors - Range of Motion (ROM)
Number of subjects: 109
Study 23217149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors - Muscle Strength
Number of subjects: 109
Study 23217149 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of clinical hip OA
Number of subjects: 109
Study 21166550 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS-based transportation device
Number of subjects: 0
Study 21166550 — intervention group
Group type: COMPARATOR
Intervention: Control group (map and verbal directions)
Number of subjects: 0
Study 17393260 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetylic salicylic acid
Number of subjects: 16
Study 15691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (49.5 g essential amino acids and 90 g carbohydrate per day for 28 days)
Number of subjects: 13
Study 15691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation
Number of subjects: 13
Study 15691900 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 13
Study 12384201 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 79
Study 12384201 — intervention group
Group type: COMPARATOR
Intervention: NGM/EE
Number of subjects: 79
Study 9564116 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care workers' evaluation using the Therapy Impact Questionnaire (TIQ)
Number of subjects: 159